ClinicalTrials.gg

Program

Encapsulated Rapamycin

Also written as “eRapa (encapsulated rapamycin)” and “Encapsulated Rapamycin (eRapa)”.

Its studies are mostly in Adenomatous Polyposis Coli · Prostatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Apr 10, 20253 company-led studies, 1 open or runningNext primary completion: Jul 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rapamycin21 open or runningphase 3since Apr 10, 2025Jan 12, 2020Jul 2030phase 3 · NCT06950385
Rapamycin Holdings, Inc. dba Emtora Biosciences10 open or runningphase 1since Jun 12, 2018Jun 12, 2018none ahead

Also a collaborator on its studies: cancer-insight-llc and biodexa-pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2018First study: phase 1 study in Prostatic NeoplasmsNew to Rapamycin Holdings, Inc. dba Emtora BiosciencesRapamycin Holdings, Inc. dba Emtora Biosciences · NCT03618355 · 15 enrolled · United States
  2. Jan 12, 2020Rapamycin's first study: phase 2 study in Adenomatous Polyposis ColiNew to RapamycinRapamycin · NCT04230499 · 30 enrolled · United States
  3. Apr 10, 2025Phase 3 study in Adenomatous Polyposis ColiRapamycin · NCT06950385 · 168 planned · United States, Denmark, Germany and more

Ahead

  1. Jul 2030Primary completion: phase 3 study in Adenomatous Polyposis ColiRapamycin · NCT06950385

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06950385Adenomatous Polyposis Coli · United States, Denmark, Germany and more3RecruitingRapamycinJul 2030168
NCT04230499Adenomatous Polyposis Coli · United States2CompletedRapamycinDec 11, 202430
NCT03618355Prostatic Neoplasms · United States1CompletedRapamycin Holdings, Inc. dba Emtora BiosciencesDec 2, 201915

How it is read

Names in the registry

  • “eRapa (encapsulated rapamycin)”, 2 entries
  • “Encapsulated Rapamycin (eRapa)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.